## -online.com Qenomics





## **Human ATL2 CRISPR gRNA in Lenti Particles**

| Overview              |  |
|-----------------------|--|
| Quantity:             | 300 μL   |
| Gene:                 | ATL2   |
| Species:              | Human  |
| Insert:               | gRNA   |
| Vector:               | Lentiviral Vector  |
| Application:          | Protein Expression (PExp), Genome Editing with Engineered Nucleases (GEEN)                                     |
| Product Details       |  |
| Purpose:              | Individual gRNA against ATL2 in Lentiviral Particles with a Titer of >1x10e7 IU/mL. (Cas9 required separately) |
| Vector Backbone:      | pLenti-U6-sgRNA-PGK-Neo  |
| Promoter:             | U6 Promoter, PGK Promoter  |
| Selectable Marker:    | Neomycin   |
| Bacterial Resistance: | Ampicillin   |
| Expression Type:      | Stable, Transient  |
| Sequence:             | Sequence available upon placing order  |
| Specificity:          | GRNAs are designed for use with Cas9 Nuclease only.  |
| Components:           | Lentiviral particles with an individual gRNA (300 $\mu$ L) for a specific sequence of ATL2                     |
| Target Details        |  |
| Gene:                 | ATL2   |
| Alternative Name:     | ATL2 (ATL2 Products)   |
| NCBI Accession:       | NR_024191  |

## **Application Details**

| Application Notes: | Recommended for quality control: Restriction Enzyme Digest and Sequencing                        |
|--------------------|--|
| Restrictions:      | For Research Use only  |
| Handling           |  |
| Format:            | Viral Particles  |
| Storage:           | -80 °C   |
| Expiry Date:       | 12 months  |
| Publications       |  |
| Product cited in:  | Johnson, Drugan, Miller, Evans: "38" in: , Vol. 1363, Issue Nucleic acids research, pp. 28-39, ( |